Immuron Limited is a verified, publicly traded biopharmaceutical company (NASDAQ: IMRN, ASX: IMC) established in 1994. Its lead product, Travelan, generates verifiable revenue (approx. AUD $4.9M in FY24) and addresses a genuine health issue (travelers' diarrhea). However, the project submission itself was of extremely low quality, containing vague claims ('most people have used my product'), incorrect data ('everyone' audience, 'null' market cap), and irrelevant tags ('web-development'). The high score reflects the verified legitimate business operations and tangible market traction, heavily penalized by the poor response quality and the niche nature of the product compared to global utility claims.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline